Phase II Open 24 Weeks Study to Evaluate Effect and Safety of Tocilizumab as the First Line Therapy in Subjects With Polymyalgia Rheumatica (PMR)
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Tocilizumab (Primary) ; Corticosteroid
- Indications Polymyalgia rheumatica
- Focus Therapeutic Use
- Acronyms TENOR
- 20 Apr 2017 Results of correction of abnormal B-cell subset distribution (n=18) published in the Rheumatology.
- 29 Feb 2016 Results published in the Annals of the Rheumatic Diseases
- 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.